drug
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
Marketedupdated 5mo agoby Novitium Pharma LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval382 co-mentions · 104 sources
- drugSYNALGOS-DC354 co-mentions · 107 sources
- drugaspirin335 co-mentions · 107 sources
- drugStem Cell Therapy for Coronavirus Disease 2019 (COVID-19)335 co-mentions · 107 sources
- tagSmall Molecule191 co-mentions · 104 sources
- drugcodeine127 co-mentions · 47 sources
- drugPROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE127 co-mentions · 47 sources
- drugPROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE127 co-mentions · 47 sources
all catalysts(30)
approval · 30
Jul 7, 1958
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Sep 6, 1983
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Sep 6, 1983
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Feb 3, 1987
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Aug 5, 1987
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Mar 5, 1999
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Jun 7, 2001
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Oct 31, 2001
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Jul 18, 2002
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Mar 13, 2006
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
May 11, 2006
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
May 9, 2013
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 16, 2016
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Aug 29, 2017
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Sep 18, 2018
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Sep 18, 2018
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Sep 18, 2018
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Oct 7, 2019
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Apr 28, 2021
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 4, 2023
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 4, 2023
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 15, 2023
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 15, 2023
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Oct 23, 2024
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Oct 31, 2024
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Nov 21, 2024
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Nov 21, 2024
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Apr 30, 2025
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 22, 2025
approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Dec 22, 2025
approval
SYNALGOS-DC (ASPIRIN) — FDA approval
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
→
Trials studying BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
- phase1Tegoprazan-Aspirin Drug Interaction in Healthy Adult Male Volunteers
- phase3Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- phase3Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
- phase1A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants
- phase2Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
- N/AThromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
- phase1Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects
- N/AHighest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 2, 2033
~6.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Mar 13, 2033method-of-use (U-1902)US 9539214
- Mar 13, 2033method-of-use (U-1902)US 9539214
- Jan 2, 2033method-of-use (U-2324)US 9987231
- Jan 2, 2033method-of-use (U-2324)US 9987231
News(4)
- White House takes stock of US-based manufacturing for 86 essential drugsThe White House's Office of Management and Budget (OMB) is asking for more information on the domestic production of 86 essential medicines, such as the pain reliever aspirin and the blood pressure…endpoints · 6d ago
- Vaccines take center stage at federal autism advisory committeeComments about vaccines overshadowed an advisory committee meeting to discuss a plan for boosting federal funding for autism research.stat · 1mo ago
- Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC PreventionColton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.onclive · 4mo ago
- Predicting consequences of new hepatitis B vaccine recsNew data on public trust in science, AI and mental health, and other news from Morning Roundsstat · 5mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that